FDA Approves First Drug for Advanced cSCC
Cemiplimab (Libtayo), approved for advanced cutaneous squamous cell carcinoma, is intended for those not eligible for curative surgery or radiation.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news